Kim Puloma Kamdar |
Kim Puloma Kamdar founded Truvian Sciences, Inc. in 2015, where she is working as Chairman. Dr. Kamdar also founded Aryzun Pharmaceuticals and Seraphina Therapeutics, Inc., where she is working as Chairman. Dr. Kamdar also currently works at Sera Prognostics, Inc., as Chairman from 2023, ROX Medical, Inc., as Director, One Palmer Square Associates VII LLC, as Director, San Diego Venture Group, as Director, The Hastings Center, as Director, Epic Sciences, Inc., as Director, Connect Foundation, as Director, SalveoDx, as Director, Evofem Biosciences, Inc., as Independent Director, Singular Genomics Systems, Inc., as Independent Director from 2017, Alume Biosciences, Inc., as Director from 2020, Epitel, Inc., as Director & Partner, Access Youth Academy, as Director, Pleno, Inc., as Director, Domain Associates LLC, as Partner from 2011, One Palmer Square Associates VIII LLC, as Managing Member, Domain LLC, as Partner from 2011, Adjuvant Capital LP, as Advisory Partner, and Medical Excellence Capital LLC, as Managing Partner from 2021. Dr. Kamdar also formerly worked at Aspen Neuroscience, Inc., as Chairman & Chief Executive Officer, Obalon Therapeutics, Inc., as Chairman from 2020 to 2021, Corthera, Inc., as Director, Novartis International AG, as Research Director, Achaogen, Inc., as Director, BiPar Sciences, Inc., as Director, Adastra Pharmaceuticals, Inc., as Director, Syndax Pharmaceuticals, Inc., as Independent Director from 2006 to 2017, Omniome LLC, as Director, Sonexa Therapeutics, Inc., as Director, Nuon Therapeutics, Inc., as Director, Altair Therapeutics, Inc., as Director, Neothetics, Inc., as Director from 2011 to 2014, Ariosa Diagnostics, Inc., as Director from 2010 to 2015, MPM BioImpact, Inc, as Principal in 2004, Torrey Mesa Research Institute, as Program Leader, and Bill & Melinda Gates Foundation, as Advisor. Dr. Kamdar received her doctorate degree in 1995 from Emory University and undergraduate degree in 1988 from Northwestern University. |